Login

Categories

Careers Consumer Corporate Energy Entertainment Experts Financials Healthcare Industrial Law Markets Media Mining Private Equity Real Estates Sports Startups Technology Venture Capital

Recent Videos

00:10:00
Revolutionizing Brain Injury Treatment: Breakthrough Trials Signal Collaborative Potential with Pharma Giants |Dr Liz Dallimore , CEO, Argenica Therapeutics Ltd.
00:10:00
Insights into AORA Biosurgery's innovative soft tissue reconstruction products, growth trajectory, and clinical trials |Brian Ward, CEO, Aroa Biosurgery Ltd .
00:10:00
Advanced cancer therapy shows promising results in licensing agreement announcement |Michael Baker, CEO, Arovella Therapeutics Ltd.
00:10:00
Innovative neuroprotective therapy ARG-007 shows promise in reducing brain cell death post-stroke, poised for phase one clinical trial |Dr Liz Dallimore , CEO, Argenica Therapeutics Ltd.
00:10:00
Empowering Women Leaders: Insights from AlbionVC's Conversation Series with Dr. Sarah Howell | Sarah Howell , CEO, Arecor Therapeutics PLC .
00:10:00
Revolutionizing Therapeutics: Advancements in RNA Medicines|Joseph E. Payne, CEO, Arcturus Therapeutics Holdings Inc.
00:10:00
"Stories of the Exchange" features CEO of Antibiotice Iași as Guest on TV |Ioan Nani, CEO, Antibiotice Iași.
00:10:00
Insightful interview with a biotech CEO discussing the company's focus on antisense therapies and the potential of their lead asset in treating Duchenne Muscular Dystrophy |James Garner, CEO,Antisense Therapeutics Ltd
00:10:00
Revolutionizing Therapy Adherence: The Single Pill Concept's Impact on Patient Well-being and Healthcare Costs |Karlheinz Gast, CEO, Apontis Pharma.
00:10:00
CEO of Aptamer Group PLC discusses anticipation of higher revenues in the second half following the release of interim results |Dr Arron Tolley, CEO, Aptamer Group PLC.
00:10:00
Insights from Aptos Biosciences CEO on Drug Development and Healthcare Systems at Blum Burton Conference | William Rice, CEO, Aptose Biosciences Inc .
00:10:00
Innovative Drug Delivery System for Patients with Swallowing Difficulties: Aquestive Therapeutics' Approach and Medications in Development | Daniel Barber, CEO, Aquestive Therapeutics Inc.
00:10:00
Our validated technology platform can produce orally active polyclonal antibodies|Steven Lydeamore,Chief Executive Officer,Immuron Ltd
00:10:00
Bringing Effective New Treatments And Options To Patients Who Need Them|Leslie Chong, CEO,Imugene Ltd
00:10:00
Unlocking the therapeutic potential of rare cannabinoids|Eric A. Adams,CEO,InMed Pharmaceuticals Inc
00:10:00
Development of a new generation of immune response modifier|Simon Wilkinson,CEO,Innate Immunotherapeutics Ltd
00:10:00
Precision medicine solutions for healthcare institutions|EMMANUELLE DEPONGE,CEO,Integragen
00:10:00
Develops its controlled-release and targeted-release oral solid dosage drugs based on its proprietary technology|Auwal Odidi,CEO,intellipharmaceutics international inc
00:10:00
A new generation of vaccines within animal health|Jonas Sohlman,CEO,Intervacc
00:10:00
Next-generation PDT that is more effective and overcomes the many shortcomings|Mr Thian Chew,CEO,Invion Ltd

© 2017 - Townhall + Tv